Onkolojide Farmakokinetik
Özet
Farmakokinetik, vücudun ilaçlar üzerindeki absorbsiyon, dağılım, metabolizma ve atılım süreçlerini inceleyen farmakoloji alt dalıdır. Dar terapötik aralığa sahip anti-neoplastik ilaçların kullanıldığı onkoloji pratiğinde farmakokinetik özelliklerin bilinmesi; tedavi başarısını artırmak, ilaç etkileşimlerini önlemek ve toksisiteyi yönetmek açısından kritik önem taşır. Tümör dokusunun değişken yapısı nedeniyle kandaki ilaç düzeyleri her zaman hedef dokudaki konsantrasyonu yansıtmaz; antineoplastiklerin normal dokulardaki düzeyi genellikle tümör dokusundan daha yüksektir. Konakçı faktörleri, intestinal engeller, karaciğer/böbrek fonksiyonları, genetik polimorfizmler (CYP2D6, UGT1A1 varyantları gibi) ve kan-beyin bariyerindeki p-glikoprotein gibi efflux pompaları ilaç emilimini, metabolizmasını ve doku penetrasyonunu doğrudan etkiler. Günümüzde kullanımı hızla artan oral antineoplastik ilaçlar (özellikle tirozin kinaz inhibitörleri), hastalar için büyük kullanım kolaylığı sağlasa da geniş farmakokinetik değişkenliğe sahiptir; bu ajanların emilimi diyet, gıda etkileşimleri ve eşlik eden komorbiditeler nedeniyle önemli ölçüde değişerek biyoyararlanımı etkileyebilir. Sonuç olarak, kanser hastalarının kırılgan yapısı ve çoklu ilaç kullanımları göz önüne alındığında, onkolojik tedavilerin farmakokinetik prensiplere göre optimize edilmesi, yan etkilerin minimize edilerek hasta konforunun ve tedavi etkinliğinin artırılmasını sağlar.
Pharmacokinetics is the sub-discipline of pharmacology that analyzes the processes of drug absorption, distribution, metabolism, and excretion by the body. In oncological practice, where anti-neoplastic drugs often feature a narrow therapeutic index, understanding pharmacokinetic properties is vital for optimizing treatment outcomes, preventing drug interactions, and managing toxicities. Due to the heterogeneous nature of tumor tissues, drug concentrations in the blood do not always accurately predict targeted tissue levels; anti-neoplastic concentrations are generally higher in normal tissues than in primary tumors. Host factors, intestinal barriers, hepatic/renal functions, genetic polymorphisms (such as CYP2D6 or UGT1A1 variants), and efflux pumps like p-glycoprotein at the blood-brain barrier directly influence drug absorption, metabolism, and tissue penetration. Although the rising use of oral antineoplastics, particularly tyrosine kinase inhibitors, offers administration convenience, they exhibit wide pharmacokinetic variability; their absorption can be significantly altered by diet, food interactions, and comorbidities, directly affecting bioavailability. Consequently, considering the fragile status of cancer patients and concurrent medications, tailoring oncological therapies based on pharmacokinetic principles ensures minimized adverse effects, reduced drug-drug interactions, and enhanced patient comfort.
Referanslar
Slordal L, Spigset O. [Basic pharmacokinetics--absorption]. Tidsskr Nor Laegeforen. 2005;125(7):886-7.
Nancarrow C, Mather LE. Pharmacokinetics in renal failure. Anaesth Intensive Care. 1983;11(4):350-60.
Gray K, Adhikary SD, Janicki P. Pharmacogenomics of analgesics in anesthesia practice: A current update of literature. J Anaesthesiol Clin Pharmacol. 2018;34(2):155-60.
Starkey ES, Sammons HM. Practical pharmacokinetics: what do you really need to know? Arch Dis Child Educ Pract Ed. 2015;100(1):37-43.
Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst. 2006;98(23):1714-23.
Liu JJ, Kestell P, Findlay M, Riley G, Ackland S, Simpson A, et al. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol. 2004;31(10):677-82.
Palm S, Enmon RM, Jr., Matei C, Kolbert KS, Xu S, Zanzonico PB, et al. Pharmacokinetics and Bio ekskresyon ribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44(7):1148-55.
Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003;2(2):123-31.
Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol. 2002;16(4):253-62.
Kirstein MN, Panetta JC, Gajjar A, Nair G, Iacono LC, Freeman BB, 3rd, et al. Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC. Cancer Chemother Pharmacol. 2005;55(5):433-8.
Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14(9):2590-611.
Gentili D, Zucchetti M, Torri V, Sessa C, de Jong J, Cavalli F, et al. A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother Pharmacol. 1993;32(6):482-6.
Colombo T, Gonzalez Paz O, Zucchetti M, Maneo A, Sessa C, Goldhirsch A, et al. Paclitaxel induces significant changes in epidoxorubicin distribution in mice. Ann Oncol. 1996;7(8):801-5.
Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zucchetti M, D'Incalci M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol. 1995;36(4):335-40.
Colombo T, Zucchetti M, D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther. 1994;269(1):22-7.
Zucchetti M, Boiardi A, Silvani A, Parisi I, Piccolrovazzi S, D'Incalci M. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol. 1999;44(2):173-6.
Garattini E, Gianni M, Terao M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action. Curr Pharm Des. 2004;10(4):433-48.
Zanette L, Zucchetti M, Freshi A, Erranti D, Tirelli U, D'Incalci M. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol. 1990;25(6):445-8.
Benfenati E, Farina P, Colombo T, De Bellis G, Capodiferro MV, D'Incalci M. Metabolism and pharmacokinetics of p-(3,3-dimethyl-1-triazeno) benzoic acid in M5076 sarcoma-bearing mice. Cancer Chemother Pharmacol. 1989;24(6):354-8.
D'Incalci M. Metabolism of triazine anticancer agents. Pharmacol Ther. 1987;35(3):291-300.
Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5(6):447-58.
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211-21.
Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res. 2003;20(1):24-30.
Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361-98.
Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927-41.
Crews KR, Stewart CF, Liu T, Rodriguez-Galindo C, Santana VM, Daw NC. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J Pediatr Hematol Oncol. 2004;26(11):764-7.
D'Incalci M, Schuller J, Colombo T, Zucchetti M, Riva A. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations. Semin Oncol. 1998;25(6 Suppl 13):16-20.
Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348(6):529-37.
Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-49.
Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815-50.
Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-8.
Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11-28.
Donelli MG, Zucchetti M, D'Incalci M. Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol. 1992;30(4):251-60.
Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97(11):2517-24.
van Asperen J, van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer. 1999;79(1):108-13.
van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst. 1996;88(14):994-9.
Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res. 2003;9(7):2849-55.
Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer. 2004;40(8):1269-74.
Arboix M, Paz OG, Colombo T, D'Incalci M. Multidrug resistance-reversing agents increase vinblastine distribution in normal tissues expressing the P-glycoprotein but do not enhance drug penetration in brain and testis. J Pharmacol Exp Ther. 1997;281(3):1226-30.
Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41(5):1967-72.
Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y, et al. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011;22(12):2604-9.
Ruggiero A, Cefalo MG, Coccia P, Mastrangelo S, Maurizi P, Riccardi R. The role of diet on the clinical pharmacology of oral antineoplastic agents. Eur J Clin Pharmacol. 2012;68(2):115-22.
Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43(15):1127-56.
